The complement response against an oncolytic virus is species-specific in its activation pathways

Molecular Therapy

Volumn 5, Issue 3, 2002, Pages 275-282

  Wakimoto, Hiroaki ^a   Ikeda, Keiro ^a   Abe, Tatsuya ^a   Ichikawa, Tomotsugu ^a   Hochberg, Fred H ^a   Ezekowitz, R Alan B ^a   Pasternack, Mark S ^a   Chiocca, E Antonio ^a  

^a MASSACHUSETTS GENERAL HOSPITAL   (United States)

Author keywords

Complement; Gene therapy; HSV 1; Viral infection

Indexed keywords

IMMUNOGLOBULIN; MANNAN BINDING LECTIN; ONCOLYTIC VIRUS; VIRUS VECTOR;

ANIMAL CELL; ARTICLE; CANCER THERAPY; COMPLEMENT ACTIVATION; CONTROLLED STUDY; HERPES SIMPLEX VIRUS; HOST RESISTANCE; IN VITRO STUDY; IN VIVO STUDY; MOUSE; NONHUMAN; QUANTITATIVE ANALYSIS; SPECIES DIFFERENCE; VIRUS INFECTION; VIRUS NEUTRALIZATION;

ANIMALIA; HUMAN HERPESVIRUS 1; MAMMALIA; RODENTIA; SIMPLEXVIRUS;

EID: 0036199737     PISSN: 15250016     EISSN: None     Source Type: Journal    
DOI: 10.1006/mthe.2002.0547     Document Type: Article

References (44)

1. Oncolytic viruses as novel anticancer agents: Turning one scourge against another
2. Conditionally replicating herpes simplex virus mutant, G207 for the treatment of malignant glioma: Results of a phase I trial
3. Treatment of intracranial gliomas in immunocompetent mice using herpes simplex viruses that express murine interleukins
4. An oncolytic viral mutant that delivers the CYP2B1 transgene and augments cyclophosphamide chemotherapy
5. Oncolytic virus therapy of multiple tumors in the brain requires suppression of innate and elicited antiviral responses
6. A critical role of natural immunoglobulin M in immediate defense against systemic bacterial infection
7. Complement depletion facilitates the infection of multiple brain tumors by an intravascular, replication-conditional herpes simplex virus mutant
8. The role of complement in inflammation and adaptive immunity
9. Structure and biology of complement protein C3, a connecting link between innate and acquired immunity
10. Complement and innate immunity
11. Baculovirus-mediated gene transfer in the presence of human serum or blood facilitated by inhibition of the complement system
12. Linkages of innate and adaptive immunity
13. A novel mechanism of retrovirus inactivation in human serum mediated by anti-α-galactosyl natural antibody
14. Complement and anti-α-galactosyl natural antibody-mediated inactivation of murine retrovirus occurs in adult serum but not in umbilical cord serum
15. Mechanism of complement inactivation by glycoprotein C of herpes simplex virus
16. In vivo role of complement-interacting domains of herpes simplex virus type 1 glycoprotein gC
17. Attenuated, replication-competent herpes simplex virus type 1 mutant G207: Safety evaluation of intracerebral injection in nonhuman primates
18. Effect of prior exposure to herpes simplex virus 1 on viral vector-mediated tumor therapy in immunocompetent mice
19. Viral shedding and biodistribution of G207, a multimutated, conditionally replicating herpes simplex virus type 1, after intracerebral inoculation in Aotus
20. A controlled trial of intratumoral ONYX-015, a selectively-replicating adenovirus, in combination with cisplatin and 5-fluorouracil in patients with recurrent head and neck cancer
21. Reovirus as a novel oncolytic agent
22. Replication-selective microbiological agents: Fighting cancer with targeted germ warfare
23. Effects of preexisting immunity on the response to herpes simplex-based oncolytic viral therapy
24. Susceptibility to HIV infection and progression of AIDS in relation to variant alleles of mannose-binding lectin
25. Complement activation upon binding of mannan-binding protein to HIV envelope glycoproteins
26. Complement-dependent neutralization of influenza virus by a serum mannose-binding lectin
27. Purification and characterization of two mannan-binding lectins from mouse serum
28. Molecular characterization of the mouse mannose-binding proteins. The mannose-binding protein A but not C is an acute phase reactant
29. Isolation and characterization of a mannan-binding protein from human serum
30. Control of early viral and bacterial distribution and disease by natural antibodies
31. Evaluation of the Galα1-3Gal epitope as a host modification factor eliciting natural humoral immunity to enveloped viruses
32. Novel mechanism of antibody-independent complement neutralization of herpes simplex virus type 1
33. Specific recognition of protein carboxy-terminal sequences by natural IgM antibodies in normal serum
34. Herpes simplex virus type 1 glycoprotein gC mediates immune evasion in vivo
35. Immune evasion properties of herpes simplex virus type 1 glycoprotein gC
36. Influenza A virus NS1 protein prevents activation of NF-(B and induction of α/β interferon
37. Humoral response to herpes simplex virus is complement-dependent
38. Cooperation between decay-accelerating factor and membrane cofactor protein in protecting cells from autologous complement attack
39. Factor H binding to bone sialoprotein and osteopontin enables tumor cell evasion of complement-mediated attack
40. Factor(s) present in herpes simplex virus type 1-infected cells can compensate for the loss of the large subunit of the viral ribonucleotide reductase: Characterization of an ICP6 deletion mutant
41. An ICP6::lacZ insertional mutagen is used to demonstrate that the UL52 gene of herpes simplex virus type 1 is required for virus growth and DNA synthesis
42. Herpes simplex virus type 1-induced ribonucleotide reductase activity is dispensable for virus growth and DNA synthesis: Isolation and characterization of an ICP6 lacZ insertion mutant
43. A mutant epidermal growth factor receptor common in human glioma confers enhanced tumorigenicity
44. Gene transfer into experimental brain tumors mediated by adenovirus, herpes simplex virus, and retrovirus vectors